^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor

Published date:
10/25/2020
Excerpt:
Of 45 evaluable pts with BRAF-mutations...10 pts (22%) achieved confirmed and mostly durable partial responses (gliomas (3), ovarian (2), and 1 each for papillary thyroid cancer, small bowel, colorectal carcinoma, anaplastic thyroid carcinoma, and melanoma).
Secondary therapy:
cobicistat
Trial ID: